Anticancer Res

1. AIZAWA R, Ogata T, Goto T, Otani T, et al
   Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI.
   Anticancer Res. 2025;45:2515-2525.
   

   >> Share

   
   
2. NGUYEN MD, Gorobets O, Djoua YJ, Rose-Dite-Modestine J, et al
   End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report.
   Anticancer Res. 2025;45:2535-2538.
   

   >> Share

   
   

   
   BMC Cancer

3. LIU Z, Gu WJ, Wan FN, Chen ZZ, et al
   Deep learning network enhances imaging quality of low-b-value diffusion-weighted imaging and improves lesion detection in prostate cancer.
   BMC Cancer. 2025;25:953.
   

   >> Share

   
   
4. QI P, Zhao J, Zhang H, Liu X, et al
   TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells.
   BMC Cancer. 2025;25:956.
   

   >> Share

   
   
5. SU R, Ye SJ, Wang SY, Zhang ZL, et al
   Ten-year follow-up of atypical small acinar hyperplasia cases diagnosed by initial prostate biopsy.
   BMC Cancer. 2025;25:964.
   

   >> Share

   
   

   
   BMC Urol

6. YANG Z, Liu Y, Shao Y, Wu Y, et al
   The comparison of outcomes between neoadjuvant novel and classical hormonal therapy in patients with locally advanced prostate cancer: a retrospective study.
   BMC Urol. 2025;25:136.
   

   >> Share

   
   

   
   Eur Urol

7. ENGLMAN C, Adebusoye B, Maffei D, Stavrinides V, et al
   Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study.
   Eur Urol. 2025 May 27:S0302-2838(25)00192-7. doi: 10.1016/j.eururo.2025.
   

   >> Share

   
   
8. LI KD, Carlisle MN, Jarosek S, Patel HV, et al
   Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data.
   Eur Urol. 2025 May 22:S0302-2838(25)00293-3. doi: 10.1016/j.eururo.2025.
   

   >> Share

   
   

   
   J Natl Cancer Inst

9. CHEN F, Paik A, Sheng X, Cheng I, et al
   Risk of aggressive prostate cancer with successive generations in the U.S. among Latino men.
   J Natl Cancer Inst. 2025 May 27:djaf119. doi: 10.1093.
   

   >> Share

   
   

   
   Lancet Oncol

10. FIZAZI K, Morris MJ, Shore ND, Chi KN, et al
    Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2025 May 26:S1470-2045(25)00189.
    

    >> Share

    
    

    
    Mod Pathol

11. JI X, Salmon R, Mulliqi N, Khan U, et al
    Physical Color Calibration of Digital Pathology Scanners for Robust Artificial Intelligence-Assisted Cancer Diagnosis.
    Mod Pathol. 2025;38:100715.
    

    >> Share

    
    

    
    Oncol Rep

12. LIU C, Tang Y, Wang J, Zhou Y, et al
    Effect of Polygonatum Sibiricum polysaccharides on nude mice model of prostate cancer PC?3 cells.
    Oncol Rep. 2025;54:84.
    

    >> Share

    
    

    
    PLoS One

13. OBENG F, Okai JNA, Sutherland E
    Predicting prostate cancer metastasis in Ghana: Comparison of multiparametric and PSA models.
    PLoS One. 2025;20:e0323180.
    

    >> Share

    
    

    
    Pol J Radiol

14. ZAREI J, Soleimani A, Tahmasbi M, Sarkarian M, et al
    Reproducibility of MRI-derived radiomic features in prostate cancer detection: a methodological approach.
    Pol J Radiol. 2025;90:e180-e188.
    

    >> Share

    
    

    
    Prostate

15. YANG P, Yang B
    A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.
    Prostate. 2025 May 26. doi: 10.1002/pros.24920.
    

    >> Share

    
    
16. ONAL C, Elmali A, Demirhan B, Guler OC, et al
    SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.
    Prostate. 2025 May 26. doi: 10.1002/pros.24919.
    

    >> Share

    
    
17. ODERDA M, Orlando G, Calleris G, Capella G, et al
    Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance.
    Prostate. 2025 May 29. doi: 10.1002/pros.24921.
    

    >> Share

    
    

    
    Radiology

18. METSER U, Zukotynski K, Mak V, Langer D, et al
    Erratum for: Effect of (18)F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.
    Radiology. 2025;315:e259010.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share